| 1.92 0.18 (10.34%) | 03-10 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.27 |
1-year : | 2.65 |
| Resists | First : | 1.94 |
Second : | 2.27 |
| Pivot price | 1.73 |
|||
| Supports | First : | 1.65 |
Second : | 1.48 |
| MAs | MA(5) : | 1.73 |
MA(20) : | 1.73 |
| MA(100) : | 1.86 |
MA(250) : | 1.24 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 53.6 |
D(3) : | 37.7 |
| RSI | RSI(14): 58.2 |
|||
| 52-week | High : | 2.64 | Low : | 0.52 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PALI ] has closed below upper band by 4.0%. Bollinger Bands are 39.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.95 - 1.95 | 1.95 - 1.96 |
| Low: | 1.72 - 1.73 | 1.73 - 1.74 |
| Close: | 1.91 - 1.92 | 1.92 - 1.93 |
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
Mon, 02 Mar 2026
Palisade Bio Announces Participation in Two Upcoming Investor Conferences - GlobeNewswire
Mon, 02 Mar 2026
Investors get two chances to question Palisade Bio in March - Stock Titan
Sun, 01 Mar 2026
Palisade Bio Details PALI-2108 UC, Crohn’s Plans and Cash Runway Into 2029 at Oppenheimer Conference - MarketBeat
Wed, 25 Feb 2026
Palisade Bio (PALI) Sees New 'Buy' Rating from Stifel | PALI Sto - GuruFocus
Wed, 25 Feb 2026
Stifel Initiates Coverage of Palisade Bio (PALI) with Buy Recommendation - Nasdaq
Tue, 24 Feb 2026
Stifel initiates Palisade Bio stock with buy rating on IBD drug - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 149 (M) |
| Shares Float | 105 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 91.8 (%) |
| Shares Short | 25,350 (K) |
| Shares Short P.Month | 17,500 (K) |
| EPS | -2.07 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.34 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -87.9 % |
| Return on Equity (ttm) | -228.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.08 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.93 |
| PEG Ratio | 0 |
| Price to Book value | 5.48 |
| Price to Sales | 0 |
| Price to Cash Flow | -28.39 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|